Home > Insider Trading > Filing (0000899243-18-011956)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1279695	Universal Biosensors Inc	UBI	Surgical & Medical Instruments & Apparatus (3841)	980424072

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1718503	L Rick Legleiter	1 Corporate Avenue Rowville Victoria C3 3178	Chief Executive Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-05-04	158,687	$0.26	158,687	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$0.50	2022-10-23	1,600,000	1,600,000	Direct
Common Stock	Stock Option (Right to Buy)	$0.60	2022-10-23	2,700,000	2,700,000	Direct
Common Stock	Stock Option (Right to Buy)	$0.80	2022-10-23	3,300,000	3,300,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2022-10-23	1,600,000	1,600,000	Direct
2022-10-23	2,700,000	2,700,000	Direct
2022-10-23	3,300,000	3,300,000	Direct

Footnotes

Traded as Chess Depository Interests ("CDIs") on the Australian Stock Exchange. CDIs represent beneficial interests in the common stock held by CHESS Depository Nominees Pty Ltd.
The price reported in Column 4 is a weighted average price and is stated in Australian dollars. These shares were purchased in multiple transactions at prices ranging from AU$0.24 to AU$0.27. The Reporting Person undertakes to provide to Universal Biosensors, Inc. ("UBI"), any security holder of UBI, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported is stated in Australian dollars.
The options were granted on October 24, 2017. The options will vest and only become exercisable on the date that is three years from the date of grant of the options, subject to continued employment at the time of vesting. If the Company terminates the employment without cause prior to the vesting date, a proportion of the options will vest, being the same as the proportion of the three year vesting period that the employee served with the Company.